Statistical Analysis Plan For Stage 1 Embarc (establishing Moderators And Biosignatures Of Antidepressant Response For Clinical Care) Study

Petkova, Eva; Ogden, R. Todd; Tarpey, Thaddeus; Ciarleglio, Adam; Jiang, Bei; Su, Zhe; Carmody, Thomas; Adams, Philip; Kraemer, Helena C.; Grannemann, Bruce D.; Oquendo, Maria A.; Parsey, Ramin; Weissman, Myrna M.; McGrath, Patrick J.; Fava, Maurizio; Trivedi, Madhukar H.

Antidepressant medications are commonly used to treat depression, but only about 30% of patients reach remission with any single first-step antidepressant. If the first-step treatment fails, response and remission rates at subsequent steps are even more limited. The literature on biomarkers for treatment response is largely based on secondary analyses of studies designed to answer primary questions of efficacy, rather than on a planned systematic evaluation of biomarkers for treatment decision. The lack of evidence-based knowledge to guide treatment decisions for patients with depression has lead to the recognition that specially designed studies with the primary objective being to discover biosignatures for optimizing treatment decisions are necessary. Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) is one such discovery study. Stage 1 of EMBARC is a randomized placebo controlled clinical trial of 8 week duration. A wide array of patient characteristics is collected at baseline, including assessments of brain structure, function and connectivity along with electrophysiological, biological, behavioral and clinical features. This paper reports on the data analytic strategy for discovering biosignatures for treatment response based on Stage 1 of EMBARC.


  • thumnail for Petkova et al. - 2017 - Statistical analysis plan for stage 1 EMBARC (Esta.pdf Petkova et al. - 2017 - Statistical analysis plan for stage 1 EMBARC (Esta.pdf application/pdf 250 KB Download File

Also Published In

Contemporary Clinical Trials Communications

More About This Work

Academic Units
Published Here
February 1, 2022